Compass Therapeutics, Inc.

NASDAQ:CMPX

Biotechnology

Healthcare
$0.61 -1.46%

-$0.03 today

Market cap
$110.03M
Beta
0.74
P/E (TTM)
-5.5
EPS (TTM)
-$0.37
52W Low $1.61High $6.88

Volume 1.79M

Average 7.64M

CMPX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Compass Therapeutics, Inc.NASDAQ: CMPX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$368K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$738K.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$368K or moves back toward the trailing-twelve-month quarterly average of -$184.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$368K+0.5% QoQ
Last fiscal yearDec 2025
-$1.47M-273.2% YoY
LTMMar 2026
-$738K-186.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-273.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(1.47M) USD
Year-over-year change
-273.2%

Gross Profit vs competitors

How CMPX compares with its peers on the latest reported figures

  • CMPX's LTM Mar 2026 gross profit of -$738K is the 8th highest of the 11 companies compared; the peer median is -$27.5K.
  • Its year-over-year change of -186.8% is the 7th highest of 8, against a peer median of -1.3%.
CMPX Competitors Peer median
Gross Profit for CMPX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$106.66M ——92.0%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$69M +1276.4%—99.1%
GOSSGossamer Bio, Inc.LTM Mar 2026$55.3M -55.6%—99.6%
OCGNOcugen, Inc.LTM Mar 2026$4.47M -1.3%-6.6%100.0%
MNPRMonopar Therapeutics Inc.LTM Mar 2026$0 ———
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$55K ———
FULCFulcrum Therapeutics, Inc.LTM Mar 2026-$338K -101.0%——
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$738K -186.8%——
OMEROmeros CorporationLTM Mar 2026-$1.23M -307.3%—12.4%
BCYCBicycle Therapeutics plcLTM Mar 2026-$7.53M +94.3%+71.2%11.9%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$10.98M +90.3%—12.4%
Peer median (excluding CMPX) -$27.5K-1.3%+32.3%92.0%

Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000850K0
Cost of Revenue00001.47M
Gross Profit000850K(1.47M)
Gross Margin———100.0%—
Research & Development20.34M30M38.12M42.34M55.97M
Selling, General & Admin10.93M11.66M12.24M15.13M16.87M
Operating Expenses81.88M41.66M50.36M57.48M71.37M
Depreciation & Amortization1.62M1.9M1.89M1.75M1.47M
EBITDA(80.19M)(34.96M)(40.6M)(47.62M)(65.02M)
EBITDA Margin———-5602.6%—
Operating Income(81.88M)(41.66M)(50.36M)(56.63M)(72.84M)
Operating Margin———-6661.8%—
Interest Income29K2.36M7.9M7.3M6.35M
Interest Expense370K2.36M000
Other Income / Expenses(299K)2.43M7.87M7.25M6.35M
Income Before Tax(82.18M)(39.23M)(42.49M)(49.38M)(66.49M)
Pre-Tax Margin———-5808.8%—
Income Tax Expense00000
Net Income(82.18M)(39.23M)(42.49M)(49.38M)(66.49M)
Net Margin———-5808.8%—
EPS (Basic)(1.31)(0.35)(0.33)(0.36)(0.42)
EPS (Diluted)(1.31)(0.35)(0.33)(0.36)(0.42)
Weighted Avg Shares62.87M105.19M127.03M137.11M157.7M
Weighted Avg Shares (Diluted)62.87M105.19M127.03M137.11M157.7M

Compass Therapeutics, Inc.

NASDAQ:CMPX

Intrinsic Alpha fair value

Locked

Current Price

$0.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.